Replies to post #209191 on Biotech Values

[mcbio]

ENTA -

The difficulty in developing RSV therapeutics (as opposed to prophylactics like Synagis) has been the sparsity of druggable targets.

Thanks. I listened to ENTA @ Leerink and they differentiated their non-fusion inhibitor approach from the fusion approach from competitors due to fact that they see resistance develop in pre-clinic to the fusion approach.